Navigation Links
Inovio Pharmaceuticals to Present at ROTH 23rd Annual Growth Stock Conference
Date:3/3/2011

BLUE BELL, Pa., March 3, 2011 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE Amex: INO), a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that Dr. J. Joseph Kim, President and CEO, will present a company overview at the ROTH 23rd Annual Growth Stock Conference being held March 13-16 at the Ritz-Carlton, Laguna Niguel, CA.

A live and archived webcast will be accessible on Inovio's website at www.inovio.com.Inovio Presentation The Ritz-CarltonMonday, March 142:30 pm PTConference details: http://www.roth.com/main/Page.aspx?PageID=7236

About Inovio Pharmaceuticals, Inc. Inovio is developing a new generation of vaccines, called DNA vaccines, to treat and prevent cancers and infectious diseases. These SynCon™ vaccines are designed to provide broad cross-strain protection against known as well as newly emergent strains of pathogens such as influenza. These vaccines, in combination with Inovio's proprietary electroporation delivery devices, have been shown to be safe and generate significant immune responses. Inovio's clinical programs include HPV/cervical dysplasia and cancer (therapeutic), avian flu (preventive), and HIV vaccines (both preventive and therapeutic). Inovio is developing universal influenza and other vaccines in collaboration with scientists from the University of Pennsylvania. Other partners and collaborators include Merck, National Cancer Institute, U.S. Military HIV Research Program, NIH, HIV Vaccines Trial Network, University of Southampton, and PATH Malaria Vaccine Initiative. More information is available at www.inovio.com.

This press release contains certain forward-looking statements relating to our business, including our plans to develop electroporation-based drug and gene delivery technologies and DNA vaccines and our capital resources. Actual events or results may differ from the expectations set forth herein as a result of a number of factors, including uncertainties inherent in pre-clinical studies, clinical trials and product development programs (including, but not limited to, the fact that pre-clinical and clinical results referenced in this release may not be indicative of results achievable in other trials or for other indications, that the studies or trials may not be successful or achieve the results desired, that results from one study may not necessarily be reflected or supported by the results of other similar studies and that results from an animal study may not be indicative of results achievable in human studies), the availability of funding to support continuing research and studies in an effort to prove safety and efficacy of electroporation technology as a delivery mechanism or develop viable DNA vaccines, the adequacy of our capital resources, the availability or potential availability of alternative therapies or treatments for the conditions targeted by the company or its collaborators, including alternatives that may be more efficacious or cost-effective than any therapy or treatment that the company and its collaborators hope to develop, evaluation of potential opportunities, issues involving product liability, issues involving patents and whether they or licenses to them will provide the company with meaningful protection from others using the covered technologies, whether such proprietary rights are enforceable or defensible or infringe or allegedly infringe on rights of others or can withstand claims of invalidity and whether the company can finance or devote other significant resources that may be necessary to prosecute, protect or defend them, the level of corporate expenditures, assessments of the company's technology by potential corporate or other partners or collaborators, capital market conditions, our ability to successfully integrate Inovio and VGX Pharmaceuticals, the impact of government healthcare proposals and other factors set forth in our Annual Report on Form 10-K for the year ended December 31, 2009, our Form 10-Q for the nine months ended September 30, 2010, and other regulatory filings from time to time. There can be no assurance that any product in Inovio's pipeline will be successfully developed or manufactured, that final results of clinical studies will be supportive of regulatory approvals required to market licensed products, or that any of the forward-looking information provided herein will be proven accurate.

CONTACTS:Investors: Bernie Hertel, Inovio Pharmaceuticals 858-410-3101 bhertel@inovio.com Media:   Jeff Richardson, Richardson & Associates 805-491-8313 jeff@richardsonglobalpr.com(Logo: http://photos.prnewswire.com/prnh/20110127/LA37605LOGO)


'/>"/>

SOURCE Inovio Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Inovio Pharmaceuticals to Present at Cowen & Co. Health Care Conference
2. Inovio Pharmaceuticals to Present at Partnering and Scientific Conferences
3. Inovio Pharmaceuticals Unveils Needle-free, Contactless Electroporation Technology for DNA Vaccine Delivery
4. Inovio Pharmaceuticals Dual-Antigen SynCon™ DNA Vaccine for Prostate Cancer Induces Robust Responses in Preclinical Trial
5. University of Southampton and Inovio Pharmaceuticals Initiate Phase 2 Clinical Study to Evaluate Leukemia DNA Vaccine Using Electroporation Delivery Technology
6. Inovio Pharmaceuticals Closes $24.3 Million Registered Offering
7. Cadence Pharmaceuticals CEO Ted Schroeder to Present at the Cowen and Company 31st Annual Health Care Conference in Boston on March 9, 2011
8. Onyx Pharmaceuticals to Present at the Cowen and Company 31st Annual Health Care Conference
9. Savient Pharmaceuticals to Present at the 31st Annual Cowen & Co. Health Care Conference
10. Accumetrics Signs Development & Supply Agreement With Portola Pharmaceuticals, Inc.
11. Handa Pharmaceuticals Announces Submission of Its First-to-File ANDA for Takedas DEXILANT®
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2016)... 5, 2016 Research ... "Europe Thalassaemia Market and Competitive Landscape Highlights ...      (Logo: http://photos.prnewswire.com/prnh/20160330/349511LOGO ) ... and Competitive Landscape Highlights - 2016, provides ... epidemiology, Thalassaemia market valuations and forecast, Thalassaemia ...
(Date:5/4/2016)... , May 4, 2016 BiondVax ... CEO, Dr. Ron Babecoff , will be attending the ... City . On Thursday, May 5, Dr. ... conference presented by Joseph Gunner & Co, taking ... BiondVax presentation that Dr. Babecoff will be using is downloadable ...
(Date:5/4/2016)... May 4, 2016 ... the  "Global Multiple Myeloma Market and Competitive ... offering.       (Logo: http://photos.prnewswire.com/prnh/20160330/349511LOGO ... and Competitive Landscape Highlights 2016, provides comprehensive ... Myeloma epidemiology, Multiple Myeloma market valuations and ...
Breaking Medicine Technology:
(Date:5/6/2016)... ... 2016 , ... Multiple award winning plumbing company in San Diego, ... Maintaining core values of exceptional customer service, quality work at reasonable rates, and giving ... in San Diego plumbing, and other services including heating & air conditioning and restoration ...
(Date:5/6/2016)... , ... May 06, 2016 , ... This Mother’s Day ... women everywhere. The 17th annual National Women’s Health Week takes place May ... Women’s Health are combining forces to empower women to make their health a top ...
(Date:5/5/2016)... ... May 05, 2016 , ... TransWipe Volume 3 is a set of 30 ... a TransWipe preset between two video clips to instantly add a unique transition to ... with customizable color and orientation options. TransWipe Volume 3 is a Final Cut Pro ...
(Date:5/5/2016)... ... May 05, 2016 , ... Textile Exchange is excited ... for public stakeholder review. The stakeholder review is an important opportunity for interested parties ... and delivers value to the wool industry., The RWS is intended to be a ...
(Date:5/5/2016)... Palm Beach, Fla. (PRWEB) , ... May 05, 2016 , ... ... Vision Institute in San Diego, California. The laser eye center will now be called ... recognized surgeons and attentive staff will remain at the full-service facility to ensure that ...
Breaking Medicine News(10 mins):